Advance Search
PENG Peiyu, ZHAO Shasha, LIANG Shan. Clinical observation of montelukast sodium combined with cetirizine hydrochloride in treatment of children with cough variant asthma[J]. Journal of Clinical Medicine in Practice, 2020, 24(7): 47-49. DOI: 10.7619/jcmp.202007014
Citation: PENG Peiyu, ZHAO Shasha, LIANG Shan. Clinical observation of montelukast sodium combined with cetirizine hydrochloride in treatment of children with cough variant asthma[J]. Journal of Clinical Medicine in Practice, 2020, 24(7): 47-49. DOI: 10.7619/jcmp.202007014
shu

Clinical observation of montelukast sodium combined with cetirizine hydrochloride in treatment of children with cough variant asthma

  • Department of Pediatrics, Xi'an Fengcheng Hospital, Xi'an, Shaanxi, 710016

More Information
  • Received Date: February 05, 2020
    Graphical Abstract
    • Abstract
  • Objective To investigate the effect of montelukast sodium combined with cetirizine hydrochloride on clinical symptoms and pulmonary function in children with cough variant asthma(CVA). Methods Totally 130 children with CVA were divided into two groups, with 65 cases in each group. The control group was treated with montelukast sodium, and the study group was treated with montelukast sodium combined with cetirizine hydrochloride. The remission time of clinical symptom, lung function index, cough symptom score and recurrence rate were compared between the two groups. Results The remission time of cough, high fever, dyspnea and time to normal result of chest X-ray in the study group were significantly shorter than those in the control group(P<0.05). After treatment, the ratio of forced expiratory volume to forced vital capacity(FEV1/FVC)and the percentage of peak expiratory flow(PEF)to the predicted normal value in both groups were significantly higher than those before treatment, and these indexes in the study group were significantly higher than those in the control group(P<0.05). After treatment, the score of cough symptoms in both groups was significantly lower than that before treatment, and the score of cough symptoms in the study group was significantly lower than that in the control group(P<0.05). The recurrence rate of the study group was 1.54%, which was significantly lower than 12.31% of the control group(P<0.05). Conclusion Montelukast sodium combined with cetirizine hydrochloride is effective in the treatment of patients with CVA, which has the advantages of rapid effect, good efficacy and low recurrence rate, and it can significantly improve the lung function of children.
    • FullText(HTML)
    • References (18)
  • 武金银. 孟鲁司特钠与布地奈德对儿童咳嗽变异性哮喘血清肿瘤坏死因子-α、免疫球蛋白E水平变化分析[J]. 安徽医药, 2018, 22(4): 750-752.
    吴昀蓉. 中西医结合治疗咳嗽变异性哮喘52例疗效观察[J]. 西部中医药, 2017, 30(3): 102-104.
    孟菁菁. 孟鲁司特钠联合布地奈德治疗咳嗽变异性哮喘的临床研究[J]. 现代药物与临床, 2017, 32(7): 1269-1272.
    王象勇. 槐杞黄颗粒联合布地奈德福莫特罗治疗儿童咳嗽变异性哮喘的临床研究[J]. 现代药物与临床, 2017, 32(12): 2392-2396.
    蒋珺. 苏黄止咳胶囊联合布地奈德吸入治疗咳嗽变异性哮喘疗效观察[J]. 现代中西医结合杂志, 2017, 26(29): 3245-3247.
    贺巧峰, 葛雯雯, 苏乐. 血锌缺乏对咳嗽变异性哮喘患儿肺功能、气道炎症和临床疗效的影响[J]. 中国儿童保健杂志, 2019, 27(3): 333-336.
    孙雪梅, 周高俊. 孟鲁司特钠治疗儿童咳嗽变异性哮喘的临床分析[J]. 北京医学, 2017, 39(8): 890-891.
    林玉平, 卢绮韵. 范冠杰教授辨治咳嗽变异性哮喘的临证经验浅析[J]. 环球中医药, 2017, 10(10): 1506-1508.
    谢梅. 止咳丸联合孟鲁司特钠治疗咳嗽变异性哮喘的临床研究[J]. 现代药物与临床, 2019, 34(9): 2654-2659.
    廖骏华, 杨华英, 张良. 左西替利嗪联合孟鲁司特治疗儿童慢性特发性荨麻疹的疗效观察[J]. 蚌埠医学院学报, 2017, 42(9): 1223-1226.
    周小强, 李高峰, 罗玉香, 等. 盐酸左西替利嗪联合白芍总苷治疗儿童慢性特发性荨麻疹的临床研究[J]. 世界中西医结合杂志, 2017, 12(11): 1542-1545.
    刘双. 半夏泻心汤联合西替利嗪治疗过敏性鼻炎的临床疗效观察[J]. 安徽医药, 2018, 22(2): 320-323.
    王基旺. 左西替利嗪对比盐酸曲普利啶治疗儿童变异性鼻炎的随机对照研究[J]. 世界临床药物, 2019, 40(7): 497-501.
    郑秀珍. 孟鲁司特钠联合盐酸西替利嗪治疗儿童咳嗽变异性哮喘的效果观察[J]. 临床合理用药杂志, 2019, 12(7): 98-99.
    杜聃峰, 孟宪勇. 盐酸西替利嗪片和盐酸左旋西替利嗪片治疗慢性特发性荨麻疹的效果和成本对比[J]. 中国处方药, 2018, 16(9): 83-84.
    胡娜, 徐晓晓, 汤磊. 孟鲁司特钠联合盐酸西替利嗪治疗儿童咳嗽变异性哮喘的疗效及对血清NT-3、EOS水平影响的研究[J]. 临床肺科杂志, 2019, 24(12): 2207-2211.
    牛宝华. 盐酸异丙嗪片与盐酸西替利嗪片联合治疗慢性荨麻疹的疗效分析[J]. 临床医药文献电子杂志, 2018, 5(42): 86-87.
    王雅琴. 孟鲁司特钠联合盐酸西替利嗪口服溶液治疗小儿咳嗽变异性哮喘的临床研究[J]. 中国药物与临床, 2019, 19(10): 1652-1654.
    • Related Articles

  • Related Articles

    [1]GUO Xiaoliang, YUAN Yu, LI Junyan, DUAN Chang'en, LIU ZHEN, MENG Linglong, LIU Hui. Predictive value of serum circRNA CDYL and circRNA ACAP2 expression levels for major adverse cardiovascular events in patients with acute myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2025, 29(5): 76-81. DOI: 10.7619/jcmp.20243434
    [2]MAO Wenqun, ZHANG Zhu, FAN Xiucai, QI Jiancheng, CHEN Xu. Changes in serum adiponectin levels after acute myocardial infarction and its relationships with heart failure and major adverse cardiac events[J]. Journal of Clinical Medicine in Practice, 2024, 28(22): 78-81, 87. DOI: 10.7619/jcmp.20242829
    [3]JI Linjuan, TIAN Xin, RUI Tao, YAO Yongwei. Predictive value of white blood cell-to-hematocrit ratio for in-hospital major adverse cardiovascular events after reperfusion therapy in patients with acute ST-segment elevation myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2024, 28(15): 14-18, 25. DOI: 10.7619/jcmp.20241932
    [4]ZHANG Junfeng, SU Shaohong. Prediction of serum indexes of major adverse cardiovascular events in acute myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2023, 27(23): 31-36, 42. DOI: 10.7619/jcmp.20231702
    [5]LU Yi, ZHANG Qian, WANG Haibo, LI Weidong. Construction and validation of predictive models for major adverse cardiovascular events in patients with acute coronary syndrome[J]. Journal of Clinical Medicine in Practice, 2023, 27(13): 87-92, 98. DOI: 10.7619/jcmp.20230857
    [6]XU Peng, BIAN Xinghua, WANG Yuhang. Effects of adipokines, inflammatory factors and intestinal flora on major adverse cardiovascular events in patients with coronary heart disease after percutaneous coronary intervention[J]. Journal of Clinical Medicine in Practice, 2023, 27(13): 81-86. DOI: 10.7619/jcmp.20231409
    [7]ZHOU Wei, DENG Yifan, ZHANG Jing. Effect of uric acid lowering therapy on content of endothelial microparticles in peripheral blood and major adverse cardiovascular events in patients with gout complicated with coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2023, 27(3): 60-63. DOI: 10.7619/jcmp.20223021
    [8]ZHANG Zhu, FAN Xiucai, TAO Liangliang, QI Jiancheng. Value of platelet-related laboratory indicators in predicting major adverse cardiovascular events of elderly patients after percutaneous coronary intervention[J]. Journal of Clinical Medicine in Practice, 2022, 26(24): 86-89, 106. DOI: 10.7619/jcmp.20222489
    [9]DENG Junjie, HU Jingxuan, LI Xinghua, LU Yao. Value of small dense low density lipoprotein cholesterol in predicting major adverse cardiovascular events of elderly patients with coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2022, 26(3): 34-38. DOI: 10.7619/jcmp.20214401
    [10]MA Ruicong, GAO Jianbo, MAO Shiyuan, ZHAO Zhihao, ZONG Jing, ZHANG Fengyun, WANG Zhirong. Predictive value of glycemic gap in predicting nosocomial major adverse cardiovascular events in patients with acute myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2022, 26(3): 29-33, 43. DOI: 10.7619/jcmp.20213795

  • Cited by

    Periodical cited type(3)

    1. 刘学伟，马新凯，李慧荣，李晓龙，乔晶. 安全转运流程管理在急危重新生儿院前急救转运过程中的应用效果评价. 婚育与健康. 2024(01): 118-120 .
    2. 关素琴，蔡一晶. 新生儿急救转运系统在危重新生儿院外转运管理中的应用. 医疗装备. 2024(08): 144-146+150 .
    3. 安蓉，蔡晓华，徐永凤. 急诊危重新生儿应用转运安全管理的效果评价. 中外医药研究. 2024(27): 75-77 .

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML
    Article views (680) PDF downloads (20) Cited by(3)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return